Menu
ncarol.com
  • Home
  • Music
  • Asheville Music
  • Entertainment
  • Business
  • Real Estate
  • Technology
  • Health
  • Books
ncarol.com

National Brain Tumor Society to Launch Campaigns Elevating the Necessity of Clinical Trials and Biomarker Testing Access
ncarol.com/10235124

Trending...
  • RAS AP Consulting Advances 1099 Education and Readiness Initiative Through IFOL Training and Finance Technology Showcase
  • ALight Technology And Services Limited Advances Through Peachscore + Dealum Accelerator and Join LvlUp Labs
  • International Misophonia Foundation Launches Sensory Accessible Technology Initiative to Address Overlooked Digital Accessibility Barriers
Joint initiatives aim to help patients and families navigate the era of precision medicine in cancer care

NEWTON, Mass. - ncarol.com -- National Brain Tumor Society (NBTS), a leader in brain tumor patient advocacy, research, information, and support, today announced the launch of two interrelated public health campaigns focused on patient awareness and access to advanced biomarker testing and clinical trials.

"While continued investment and concerted drug development efforts are certainly needed, the precision medicine era has arrived for patients with brain tumors," said David Arons, president and chief executive officer of NBTS. "With the World Health Organization's two recent reclassifications of central nervous system tumors in 2016 and 2021, patients with brain tumors need more precise diagnoses. These recent advances in the understanding of the molecular characteristics of tumor types, as well as new drug approvals and encouraging results from recent clinical trials, call for a greater understanding of patient options from the point of diagnosis. We want to ensure that brain tumors undergo comprehensive biomarker analysis and that patients and their care partners better understand and have improved access to clinical trials and expanded access options that might be their best source of care. To achieve this result, the NBTS campaigns will inform patients, seek improved coverage from insurers, and work with providers."

More on ncarol.com
  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
  • Brian G. Miller Co., LLC Receives Tier 1 Ranking in the 2027 Edition of Best Law Firms®
  • The Villari Firm, PLLC Named to the 2027 Edition of Best Law Firms
  • Bacchus Wine & Spirits and Michelin Guide–Recommended Ethel's Fancy to Host Exclusive LOUIS XIII Limited Edition Diwali Decanter Celebration
  • Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs

NBTS is launching the campaigns based on data on educational gaps in the brain tumor community gathered via a broad survey. Data collection analysis will inform future strategies, in addition to already planned educational and engagement activities.

The campaigns are being launched and developed with the generous support from Bayer, Danaher Foundation, and Servier Pharmaceuticals.

About the National Brain Tumor Society

Building on over 30 years of experience, the National Brain Tumor Society (NBTS) unrelentingly invests in, mobilizes, and unites the brain tumor community to discover a cure, deliver effective treatments, and advocate for patients and caregivers. Our focus on defeating brain tumors and improving the quality of patients' lives is powered by our partnerships across science, healthcare, policy, and business sectors. We fund treatments-focused research and convene those most critical to curing brain tumors once and for all. Join us at BrainTumor.org.

Contact
Tom Halkin
National Brain Tumor Society
***@braintumor.org


Source: National Brain Tumor Society

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • PropAccount.com Launches PropWallet, Turning Prop Firm Payouts Into Repeat Sales
  • Tonight in Asheville: KayeDinero Drops "Underground" and Opens Beat Catalog
  • KOLBUS America, For All Of Your Hycorr Equipment And Service Needs
  • Heritage at Hopewell Announces New 3.875% Year-One Mortgage Rate Buydown Incentive on Quick Delivery Townhomes (7.11% APR)
  • New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc
  • Prince's Collaborator Shelby J To Be A Special Guest For "a Deadly Proposal" Red Carpet
  • Rent a Truck or Hire Movers? New Data Shows Fuel Now Makes Up to 40% of DIY Moving Costs
  • 7th Annual RACE INDUSTRY WEEK Returns Nov. 30 – Dec. 3 With Free Live Webinars From Racing Leaders
  • Club Wyndham Research Identifies the "Holiday Rewind Effect": 93% of Parents Recreate Their Own Childhood Holidays for Their Kids
  • IEI Rugged IP66 Panel PC Brings Real-Time Visibility to Heavy-Duty Mining Fleets
  • AQUALIS of Morrisville, NC, Acquires Full Circle Environmental of Garner, NC
  • FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
  • Building a Technology Powerhouse-From AI Drones and Global Acquisitions to Defense, Enterprise Software and the Future of Autonomous Operations $ZENA
  • Shelter Structures America backs MATRA Second Life Project to turn retired tent vinyl into homes for displaced families
  • P-Wave Press Announces Becoming Dad: Reflections for New Fathers by L. A. Davenport
  • Logicraft Launches FuelDeck™, AI That Turns Aviation Fuel Tickets Into One Traceable Ledger
  • Inaugural OC Tech Week Draws 3,000 From 12 Countries, Sends Finalist to $1M Startup World Cup
  • Award-Winning American Hotelier Opens Art-Filled Luxury Cottage in Norfolk, England
  • Young Author Taraji Jones Surpasses 100 Amazon Book Sales
  • K2 Global / Ozi Amanat Named Among Top 100 AI Venture Capitalists in 2026
_catLbl0 _catLbl1

Popular on ncarol.com

  • Constantine "Costa" Kapothanasis II Acquires The Lubri-Loy Company, Carrying a 77-Year-Old American Lubricant Brand Into Its Next Era - 228
  • Parade of Homes Winners Announced - 208
  • LowSignalMail Lets Users Handle Gmail by Text Message - 207
  • North Carolina Author Carrie Sybert Celebrates Three Published Books - 171
  • Nious Media Expands Independent Entertainment Network Through Gaming, Music and Digital Storytelling - 169
  • Thunderbird F-16 Arrives 11/11 - 145
  • LCM Company Explains Professional Upholstery Cleaning in Charlotte, NC - 140
  • B Street Productions Announces Red Carpet Premiere Of Thriller "a Deadly Proposal" In North Car - 124
  • Air Force Veteran Sean Douglas Delivers Powerful Suicide Prevention Presentations to Hundreds of Marines at Camp Pendleton - 110
  • 450 Million Revenue Run Rate, Global Telecom Reach and a New Digital Growth Opportunity Take Center Stage: IQSTEL, Inc. (N A S D A Q: IQST) - 107

Similar on ncarol.com

  • New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
  • Lake Norman Philharmonic - Free Holiday Concert
  • Kestrel Ridge Health Launches AI-Powered Ophthalmology Workforce Forecasting Platform
  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
  • New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
  • New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc
  • FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
  • Shelter Structures America backs MATRA Second Life Project to turn retired tent vinyl into homes for displaced families
  • International Misophonia Foundation Launches Sensory Accessible Technology Initiative to Address Overlooked Digital Accessibility Barriers
  • Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute